This has direct therapeutic relevance, especially considering the recent DESTINY-Breast04, in which a new category of breast cancer patients, HER2-low, had PFS and OS meaningfully improved by use of trastuzumab deruxtecan (TDxd)81, leading to FDA approval for use of TDxd for this indication. This evidence concerns the gene ERBB2 and breast carcinoma.